BTK News

News

Zanubrutinib Shows Promise for Patients With B-Cell Malignancies Intolerant of Other BTK Inhibitors

04/10/2023

Results of a phase 2 trial indicate that using zanubrutinib as a treatment for b-cell malignancies yielded safe and effective results among patients intolerant of other BTK inhibitors.

Results of a phase 2 trial...

04/10/2023

Oncology

News

Ibrutinib Plus Lenalidomide and Rituximab Among Patients With R/R DLBCL

04/04/2023

Jordan Kadish ;

Results of a phase 2 trial indicate that BTK inhibitor ibrutinib plus lenalidomide and rituximab led to antitumor activity with durable responses among patients with relapsed/refractory diffuse large B-cell lymphoma.

Results of a phase 2 trial...

04/04/2023

Oncology

News

Novel BTK Inhibitor DTRMWXHS-12 Plus Everolimus and Pomalidomide for Hematologic Malignancies

04/04/2023

Jordan Kadish ;

Results of a phase 1 trial suggest that DTRMWXHS-12, a novel BTK inhibitor, plus everolimus and pomalidomide yielded safe and effective results among patients with relapsed/refractory hematologic malignancies.

Results of a phase 1 trial...

04/04/2023

Oncology

News

Zanubrutinib Yields Superior PFS and ORR Compared to Ibrutinib for Patients With R/R CLL/SLL

02/09/2023

Jordan Kadish ;

A final analysis of the ALPINE randomized phase 3 study found that zanubritinib for patients with R/R CLL/SLL resulted in superior progression-free survival and overall remission rate compared with ibrutinib.

A final analysis of the ALPINE...

02/09/2023

Oncology

News

FDA Approves Pirtobrutinib for Relapsed/Refractory Mantle Cell Lymphoma

01/27/2023

On January 27, 2023, the FDA granted accelerated approval to pirtobrutinib for relapsed/refractory mantle cell lymphoma (MCL) after at least 2 lines of systemic therapy, including a BTK inhibitor.

On January 27, 2023, the FDA...

01/27/2023

Oncology

News

Zanubrutinib Improved Long-Term Response Rates for Patients With Waldenström Macroglobulinemia

10/17/2022

According to a long-term analysis of a phase 3 study, Bruton tyrosine kinase inhibitor zanubrutinib had higher complete response and clinically meaningful advantages in long-term safety and tolerability versus ibrutinib in Waldenström...

According to a long-term...

10/17/2022

Oncology

News

Pirtobrutinib Demonstrates Promising Efficacy in Mantle Cell Lymphoma Following BTK Inhibitor Treatment

10/11/2022

Gina Tomaine ;

Pirtobrutinib demonstrated promising efficacy in heavily pretreated, poor-prognosis mantle cell lymphoma following multiple prior lines of therapy, including with a covalent BTK inhibitor, according to a recent phase 1/2 study.

Pirtobrutinib demonstrated...

10/11/2022

Oncology

News

BTK Inhibitor Yields Promising Results in CLL Resistant to Venetoclax

09/01/2020

BTK inhibitor therapy showed lasting disease control in a study of patients with CLL resistant to venetoclax.

BTK inhibitor therapy showed...

09/01/2020

Oncology

News

FDA Approves Brexucabtagene Autoleucel for Adults With Relapsed/Refractory MCL

07/27/2020

The FDA has given brexucabtagene autoleucel accelerated approval for the treatment of adults with relapsed or refractory MCL.

The FDA has given brexucabtagene...

07/27/2020

Oncology

News

Twice-Daily Dosing of Acalabrutinib Well-Tolerated, Effective for BTK Inhibition in CLL

07/17/2020

In a study of patients with CLL, acalabrutinib was clinically effective, with twice daily dosing maintaining near-complete occupancy of BTK in blood and tissues than once daily dosing.

In a study of patients with CLL,...

07/17/2020

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology